Centers for Disease Control: Annual Summary 1983. MMWR32:121,1984
2.
Kessner DM, Snow CK, Singer J.: Assessment of medical care for children: Contrast in health status. National Academy of Sciences Institute of Medicine, Washington DC3:38-54,1974
3.
Lisby-Sutch SM, Nemec-Dwyer MA, Deeter RG, et al: Therapy of otitis media. Clin Pharm9:15-34, 1990
4.
Nelson JD: Pocketbook of Pediatric Antimicrobial Therapy 1989-1990 (ed 8). Baltimore, MD, Williams & Wilkins, 1989, pp 27-28
5.
Berman S., Grose K., Nuss R., et al: Management of chronic middle ear effusion with prednisone combined with trimethoprim-sulfamethoxazole. Pediatr Infect Dis J9:533-538,1990
6.
McCracken GH : Management of acute otitis media with effusion . Pediatr Infect Dis J7:42-445,1988
Gerber MA, Spadaccini LJ, Wright LL, et al: Twice daily penicillin in the treatment of streptococcal pharyngitis . Am J Dis Child139:1145-1148,1985
9.
Gerber MA, Randolph MF, DeMeo K., et al: Failure of once-daily penicillin V therapy for streptococcal pharyngitis. Am J Dis Child143:153-155, 1989
10.
Brook I.: Role of beta lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococci. Pediatr Infect Dis4:491-495, 1985
11.
Chaudhary S. , Bilinskgy SA, Hennessey JL, et al: Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: A randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final four days of therapy. J Pediatr106:481-486, 1985
12.
Tanz RR, Shulman ST, Barthel MJ, et al: Penicillin plus rifampin eradicates pharyngeal carriage of group A Streptococci. J Pediatr106:876-880, 1985
13.
George WL, Finegold SM: Bacterial infections of the lung. Chest81:502-507, 1982
14.
Koster F.: Respiratory infections, in Barker LR, Burton JR, Zieve PD (eds): Principles of Ambulatory Medicine (ed 2). Baltimore, MD, Williams & Wilkins, 1986, pp 347-363
15.
Carden DL, Smith JK: Pneumonias. Emerg Med Clin North Am7:255-277, 1989
16.
Reed MD, Witte MK: Lower respiratory tract infections, in DiPiro JT, Talbert RL, Hayes PE, et al (eds): Pharmacotherapy: A Pathophysiologic Approach (ed 1). New York, NY , Elsevier, 1989, pp 1089-1105.
17.
Sanford JP: Guide to Antimicrobial Therapy 1990. West Bethesda, MD , Antimicrobial Therapy Inc, 1990
18.
Rowe PC: The Harriet Lane Handbook (ed 11). Chicago, IL, Year Book Medical, 1987
19.
Dolin R., Reichman RC, Madore HP, et al: A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med307:580-589, 1982
20.
Reele SB: Adverse drug experiences during rimantadine trials. J Respir Dis8:81-96,1987 (suppl)
21.
Brady MT, Sears SD, Pacini DL, et al: Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic. Antimicrob Agents Chemother34:1633-1636, 1990
22.
Crumpacker C., Marlowe S., Zhang JL, et al: Treatment of cytomegalovirus pneumonia . Rev Infect Dis10:538-546,1988 (suppl)
23.
Janai HK, Marks MI, Zaleska M., et al: Ribavirin: Adverse drug reactions 1986 to 1989. Pediatr Infect Dis J9:209-211, 1990
24.
Carden DL, Gibb KA: Pneumonia and lung abscess. Emerg Med Clin North Am1:345-370,1983
25.
Levison ME, Kaye D.: Pneumonia caused by gram-negative bacilli: An overview. Rev Infect Dis7:656-665, 1985 (suppl 4)
26.
Moore RD, Smith CR, Lietmen PC: The association of aminoglycoside plasma level with therapeutic outcome in gram-negative pneumonia. Am J Med77:657-662, 1984
27.
Bodem CR, Lampton LM, Miller DP, et al: Endobronchial pH. Relevance to aminoglycoside activity in gramnegative bacillary pneumonia. Am Rev Respir Dis127:39-41, 1983
28.
Dahlgren JG, Anderson ET, Hewitt WL, et al: Gentamicin blood levels: A guide to nephrotoxicity. Antimicrob Agents Chemother8:58-62, 1975
29.
Zaske DE: Aminoglycosides, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics (ed 2). Spokane, WA, Applied Therapeutics Inc, 1986, p 369
30.
Centers for Disease Control: General recommendations on immunization. MMWR38:205-227,1989
